A proprietary lead compound that expands hematopoietic and progenitor cells ex vivo has been shown to be able to generate sufficient amount of blood stem cells product for a clinically meaningful dose in adult transplant patient. Expanded grafts showed excellent functionality upon engraftment in immunodeficient mice.
TECHNOLOGY FEATURES & SPECIFICATIONS
Unique features of the lead compound as an expansion agent: 1) allows faster and lasting engraftment, 2) multi-lineage repopulation capacity of expanded graft in primary recipient mice, 3) freeze-thaw tolerant grafts with respect to in vivo repopulation capacity, 4) expanded cells that are free of karyotypic alterations and leukemic morphology, 5) the only known small molecule that expands cord blood without prior CD34+ enrichment.
Hematopoeitic stem and progenitor cell expansion for transplantation targeting acute leukemias, lymphoma and myelodysplasia as primary indications
Off-the-shelf therapy to improve outcomes in intensive chemotherapy
Expansion of grafts in cell banks
Expansion for gene therapy application